GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults
- Conditions
- Interventions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 86
- Registration Number
- NCT00239577
- Locations
- 🇺🇸
GSK Investigational Site, Silver Spring, Maryland, United States
Safety of GlaxoSmithKline (GSK) Biologicals Hepatitis A Vaccine in Korean Population
- Conditions
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 600
- Registration Number
- NCT00237991
Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy
- First Posted Date
- 2005-10-10
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 539
- Registration Number
- NCT00235755
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇺🇸Neurological Clinic-Texas, Dallas, Texas, United States
🇩🇪University of Bonn -- Department for Epileptplogy, Bonn, Germany
Rosiglitazone And Plaque Study for Type 2 Diabetes Mellitus
- Conditions
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT00231387
- Locations
- 🇬🇧
GSK Clinical Trials Call Center, London, United Kingdom
Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 306
- Registration Number
- NCT00232596
- Locations
- 🇺🇸
McFarland Clinic, Ames, Iowa, United States
🇺🇸Oregon Neurology PC, Tualatin, Oregon, United States
🇦🇷Fundacion Lennox, Cordoba, CRD, Argentina
Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.
- Conditions
- Interventions
- Biological: HPV-16/18/31/45 L1 AS04 Formulation 3Biological: HPV-16/18/31/45 L1 AS04 Formulation 4Biological: HPV-16/18/31/45 L1 AS04 Formulation 6Biological: HPV 16/18 L1 AS04Biological: HPV-16/18/31/45 L1 AS04 Formulation 1Biological: HPV-16/18/31/45 L1 AS04 Formulation 2Biological: HPV-16/18/31/45 L1 AS04 Formulation 5
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 383
- Registration Number
- NCT00231413
- Locations
- 🇧🇪
GSK Investigational Site, Wilrijk, Belgium
Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children
- Conditions
- Interventions
- First Posted Date
- 2005-09-29
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 798
- Registration Number
- NCT00228917
- Locations
- 🇹🇭
GSK Investigational Site, Bangkok, Thailand
Assess the Non-inferiority of GSK Biologicals' Mencevax™ ACWY (Manufactured by a New Process) vs Mencevax™ ACWY (the Already Existing Vaccine in the Market) When Given as a Single Dose to Subjects Aged 2-30 Yrs
- Conditions
- First Posted Date
- 2005-09-28
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 324
- Registration Number
- NCT00227422
- Locations
- 🇱🇧
GSK Investigational Site, Beirut, Lebanon
Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox
- Conditions
- Interventions
- First Posted Date
- 2005-09-27
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 5803
- Registration Number
- NCT00226499
- Locations
- 🇸🇪
GSK Investigational Site, Örebro, Sweden
Study In Adults And Adolescents With Seasonal Allergic Rhinitis.
- Conditions
- First Posted Date
- 2005-09-26
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 288
- Registration Number
- NCT00225823
- Locations
- 🇸🇪
GSK Investigational Site, Ängelholm, Sweden